ASTRAZENECA PLC DL-,25/ GB0009895292 /
2024-07-22 8:08:11 AM | Chg. +1.75 | Volume | Bid8:59:34 PM | Ask8:59:34 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
145.15EUR | +1.22% | 0 Turnover: 0.00 |
145.50Bid Size: 40 | 146.15Ask Size: 40 | 225.72 bill.EUR | - | - |
GlobeNewswire
06-26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
06-18
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-13
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire
05-08
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire
05-06
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire
05-02
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
03-28
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...